COVID-19 New Variation Vaccine
COVID-19 Vaccine For New Variants
The purpose of this study is to learn if an investigational formulation of a new COVID-19 vaccine is safe and can help the body produce antibodies to fight off new COVID-19 variants.
This is study is enrolling participants aged 12 and older.
Eligible participants can expect:
- To be enrolled in the study for about six months, with 5 scheduled visits with the study site staff
- Study vaccines and study-related procedures to be provided at no cost
- Up to $660 compensation for time and travel for eligible participants
*Other conditions may apply
Contribute to the advancement of medical knowledge and treatments, while receiving expert medical care under close supervision.
The M3 Wake Research Network has powered innovation with over 9,100 Successful Clinical Trials in patients from 6 months to 85 years.
Patient safety is paramount with strict protocols and ethical guidelines, minimizing risks and ensuring thorough monitoring throughout the trial.